Engineering of levodopa inhalable microparticles in combination with leucine and dipalmitoylphosphatidylcholine by spray drying technique.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Dec 2021
Historique:
received: 15 06 2021
revised: 05 09 2021
accepted: 12 09 2021
pubmed: 17 9 2021
medline: 18 11 2021
entrez: 16 9 2021
Statut: ppublish

Résumé

The aim of this work was to study the effect of concomitant use of leucine and dipalmitoylphosphatidylcholine, in different ratios, on aerosolization performance of levodopa. Three-component formulations were selected based on a central composite design using percentages of leucine and dipalmitoylphosphatidylcholine as the independent variables. Particle size, surface roughness index, surface phosphorus and fine particle fraction were considered as dependent variables in the model. The spray dried samples were also characterized to determine their particle shape and solid state nature. levodopa was spray dried with 10-40% w/w of the excipients to prepare two- or three-component formulations. A crystalline nature was determined for levodopa in all samples spray dried from water:ethanol (30:70 v/v). Roughness in surface of the processed particles increased with increasing total concentration of the excipients, specially above 25% w/w. Analysis of phosphorus on the surface demonstrated that three-component formulations prepared with combination of 12.5% w/w leucine had the highest amount of dipalmitoylphosphatidylcholine in the surface, regardless of its percentage used in the initial feed. A combination of 12.43% w/w of leucine and 9.80% w/w of dipalmitoylphosphatidylcholine used in formulation exhibited the highest fine particle fraction (72.63%). It can be concluded that spray drying of levodopa with a suitable combination of both excipients leads to production of a three-component formulation of crystalline levodopa, with an aerosolization performance which is significantly higher than two-component formulations composed of the drug with either leucine or dipalmitoylphosphatidylcholine.

Identifiants

pubmed: 34530077
pii: S0928-0987(21)00311-0
doi: 10.1016/j.ejps.2021.106008
pii:
doi:

Substances chimiques

Aerosols 0
Powders 0
1,2-Dipalmitoylphosphatidylcholine 2644-64-6
Levodopa 46627O600J
Leucine GMW67QNF9C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106008

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Sara Bahrainian (S)

Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Sadat Mirmoeini (MS)

Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Zahra Gilani (Z)

Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Kambiz Gilani (K)

Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: gilani@tums.ac.ir.

Articles similaires

Aerosols Humans Decontamination Air Microbiology Masks
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal
Calcium Carbonate Sand Powders Construction Materials Materials Testing
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin

Classifications MeSH